QRGenetics

Company Overview

Snapshot

Founded in June 2019 by Shane Wald-Altman, Dan Lavi, and Miguel Weil, QRGenetics operates with 1–10 employees. The company secured a grant in December 2023 from Israel Investment Partners (IIP), marking a significant milestone in its development.

Business overview

QRGenetics develops an AI-supported drug discovery engine focused on identifying potential therapies for common genetic diseases. The company's core technology utilizes exclusive spatial analytics and proprietary omics datasets to rapidly discover novel drug-target combinations, including new applications for drugs nearing patent expiration. Serving the global pharmaceutical and biotechnology sectors, QRGenetics aims to address genetic diseases without current treatments or unknown mechanisms of action, advancing precision medicine.

Strategic signal

In December 2022, QRGenetics was featured in an N12 article highlighting a breakthrough in rare genetic disease research, specifically mentioning its AI-powered platform. This media attention signals growing recognition for the company's innovative approach to drug discovery and its potential to impact the treatment landscape for genetic disorders, attracting further interest from the scientific and investment communities.

Company Intelligence Q&A

What is QRGenetics' primary focus in drug discovery?

QRGenetics focuses on identifying potential therapies for common genetic diseases by uncovering new treatments for patients with similar rare-disease mutations, utilizing an AI-supported drug discovery engine.

When was QRGenetics founded and by whom?

QRGenetics was founded in June 2019 by Shane Wald-Altman, Dan Lavi, and Miguel Weil.

What significant funding event did QRGenetics participate in?

In December 2023, QRGenetics secured a grant from Israel Investment Partners (IIP).

What technology does QRGenetics leverage in its drug discovery process?

QRGenetics' drug discovery engine utilizes exclusive spatial analytics and proprietary omics datasets to rapidly produce novel drug and target combinations.

What market does QRGenetics primarily serve?

QRGenetics serves the global market, with a focus on pharmaceutical companies and the biotechnology sector, addressing genetic disorders and rare diseases.